Kirkland & Ellis advised SciClone Pharmaceuticals on the offer.SciClone Pharmaceuticals (Holdings) Limited (HKSE: 6600) announced its HK$780 million voluntary conditional cash offer to buy-back up to 77,534,791…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
